首页> 美国卫生研究院文献>other >Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

【2h】

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

机译：I期药代动力学和生物分布研究逐步增加去势抵抗性转移性前列腺癌男性患者的223 Ra-二氯化物剂量

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose²²³Ra-Dichloride (²²³Ra) is a novel bone-seeking alpha-emitter that prolongs survival in patients with castration-resistant metastatic prostate cancer. We conducted a study to better profile the pharmacokinetics, pharmacodynamics, and biodistribution of this agent.

机译：目的^{223 二氯化镭（^{223 Ra）是一种新型的寻骨头α-发射体，可延长去势抵抗性转移性前列腺癌患者的生存期。我们进行了一项研究，以更好地描述该药物的药代动力学，药效学和生物分布。}}

著录项

期刊名称 other
作者
Jorge A. Carrasquillo; Joseph A. O’Donoghue; Neeta Pandit-Taskar; John L. Humm; Dana E. Rathkopf; Susan F. Slovin; Matthew J. Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M. Larson; Howard I. Scher; Michael J. Morris;
展开▼
作者单位

展开▼
年(卷),期 -1(40),9
年度 -1
页码 1384–1393
总页数 22
原文格式 PDF
正文语种
中图分类
关键词
Bone metastases Prostate cancer sup223/supRa Radium Radionuclide therapy Alpharadin;

机译：骨转移;前列腺癌;sup 223 / sup Ra;镭;放射性核素治疗;阿法拉丁;

相似文献

外文文献
中文文献
专利

1. Phase i pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer [J] . CarrasquilloJ.A., ODonoghueJ.A., Pandit-TaskarN., European Journal of Nuclear Medicine and Molecular Imaging . 2013,第9期

机译：逐步增加剂量的223 Ra-二氯化物在去势抵抗性转移性前列腺癌男性中的一期药代动力学和生物分布研究
2. A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2020,第5期

机译：烯醇酰胺与AKT抑制剂AZD5363（Capivasertib）与转移性阉割的前列腺癌患者组合的I代升级研究
3. Phase i dose-escalation and pharmacokinetic study (TED 11576) of cabazitaxel in Japanese patients with castration-resistant prostate cancer [J] . MukaiH., TakahashiS., NozawaM., Cancer chemotherapy and pharmacology. . 2014,第4期

机译：卡巴他赛在日本去势抵抗性前列腺癌患者中的第一阶段剂量递增和药代动力学研究（TED 11576）
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial [O] . Ravi A Madan, Mahsa Mohebtash, Philip M Arlen, -1

机译：易普利姆玛和转移性去势抗性前列腺癌的疫苗痘病毒靶向前列腺特异抗原：相位1的剂量递增试验
7. Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer [O] . Jorge A. Carrasquillo, Joseph A. O’Donoghue, Neeta Pandit-Taskar, 2013

机译：在抗阉割转移前列腺癌中升级223ra-dichloride的升级剂量的药代动力学和生物分布研究

Phase I pharmacokinetic and biodistribution study with escalating doses of 223Ra-dichloride in men with castration-resistant metastatic prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅